Liver Illness Visibility, Education, and Research Act of 2019
Do you support it?
Want to know if it passes?
We'll email you when S 3074 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on S 3074.
You're tracking S 3074
We'll email you the moment it moves.
S 3074 — Liver Illness Visibility, Education, and Research Act of 2019
Last action — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
2In Committee
-
3Passed Senate
-
4Passed House
-
5To Executive
-
6Enacted
This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Bill Text
- Introduced Introduced in Senate Current html December 17, 2019
Sections of law this bill changes
11 sections in 1 lawFrom the bill's own amending language, matched to the official United States Code (current through Public Law 119-121).
Public health service · 42 U.S.C. ch. 6A 8 sections Amends the act as a whole
-
§ 281 Organization of National Institutes of Health Amends
42 U.S.C. § 281 — at 281(b)(3)
The law today
(a) Relation to Public Health Service The National Institutes of Health is an agency of the Service. (b) National research institutes and national centers The following agencies of the National Institutes of Health are national research institutes or national centers: (1) The National Cancer Institute. (2) The National Heart, Lung, and Blood Institute. (3) The National Institute of Diabetes and Digestive and Kidney Diseases. (4) The National Institute of Arthritis and Musculoskeletal and Skin Diseases. (5) The National Institute on Aging. (6) The National Institute of Allergy and Infectious Diseases. (7) The Eunice Kennedy Shriver National Institute of Child Health and Human Development. (8) The National Institute of Dental and Craniofacial Research. (9) The National Eye Institute. (10) The National Institute of Neurological Disorders and Stroke. (11) The National Institute on Deafness and Other Communication Disorders. (12) The National Institute on Alcohol Abuse and Alcoholism. (13) The National Institute on Drug Abuse. (14) The National Institute of Mental Health. (15) The National Institute of General Medical Sciences. (16) The National Institute of Environmental Health Sciences. (17) The National Institute of Nursing Research. (18) The National Institute of Biomedical Imaging and Bioengineering. (19) The National Human Genome Research Institute. (20) The National Library of Medicine. (21) The National Center for Advancing Translational Sciences. (22) The John E. Fogarty International Center for Advanced Study in the Health Sciences. (23) The National Center for Complementary and Integrative Health. (24) The National Institute on Minority Health and Health Disparities. (25) Any other national center that, as an agency separate from any national research institute, was established within the National Institutes of Health as of the day before January 15, 2007. (c) Division of Program Coordination, Planning, and Strategic Initiatives (1) In general Within the Office of the Director of the National Institutes of Health, there shall be a Division of Program Coordination, Planning, and Strategic Initiatives (referred to in this subsection as the “Division”). (2) Offices within Division (A) Offices The following offices are within the Division: The Office of AIDS Research, the Office of Research on Women’s Health, the Office of Behavioral and Social Sciences Research, the Office of Disease Prevention, the Office of Dietary Supplements, and any other office located within the Office of the Director of NIH as of the day before January 15, 2007. In addition to such offices, the Director of NIH may establish within the Division such additional offices or other administrative units as the Director determines to be appropriate. (B) Authorities Each office in the Division— (i) shall continue to carry out the authorities that were in effect for the office before January 15, 2007; and (ii) shall, as determined appropriate by the Director of NIH, support the Division with respect to the authorities described in section 282(b)(7) of this title. (d) Organization (1) Number of institutes and centers In the National Institutes of Health, the number of national research institutes and national centers may not exceed a total of 27, including any such institutes or centers established under authority of paragraph (2) or under authority of this subchapter as in effect on the day before January 15, 2007. (2) Reorganization of institutes (A) In general The Secretary may establish in the National Institutes of Health one or more additional national research institutes to conduct and support research, training, health information, and other programs with respect to any particular disease or groups of diseases or any other aspect of human health if— (i) the Secretary determines that an additional institute is necessary to carry out such activities; and (ii) the additional institute is not established before the expiration of 180 days after the Secre...68 other bills also change this section · Follow it → Official text at uscode.house.gov ↗
-
§ 284e Research on osteoporosis, Paget’s disease, and related bone disorders Amends
42 U.S.C. § 284e — at 284e(a)
The law today
(a) Establishment The Directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute on Aging, the National Institute of Dental Research, and the National Institute of Diabetes and Digestive and Kidney Diseases, shall expand and intensify the programs of such Institutes with respect to research and related activities concerning osteoporosis, Paget’s disease, and related bone disorders. (b) Coordination The Directors referred to in subsection (a) shall jointly coordinate the programs referred to in such subsection and consult with the Arthritis and Musculoskeletal Diseases Interagency Coordinating Committee and the Interagency Task Force on Aging Research. (c) Information clearinghouse (1) In general In order to assist in carrying out the purpose described in subsection (a), the Director of NIH shall provide for the establishment of an information clearinghouse on osteoporosis and related bone disorders to facilitate and enhance knowledge and understanding on the part of health professionals, patients, and the public through the effective dissemination of information. (2) Establishment through grant or contract For the purpose of carrying out paragraph (1), the Director of NIH shall enter into a grant, cooperative agreement, or contract with a nonprofit private entity involved in activities regarding the prevention and control of osteoporosis and related bone disorders.4 other bills also change this section · Follow it → Official text at uscode.house.gov ↗
-
§ 285c-1 Data systems and information clearinghouses Amends
42 U.S.C. § 285c-1
The law today
(a) National Diabetes Data System and National Diabetes Clearinghouse The Director of the Institute shall (1) establish the National Diabetes Data System for the collection, storage, analysis, retrieval, and dissemination of data derived from patient populations with diabetes, including, where possible, data involving general populations for the purpose of detection of individuals with a risk of developing diabetes, and (2) establish the National Diabetes Information Clearinghouse to facilitate and enhance knowledge and understanding of diabetes on the part of health professionals, patients, and the public through the effective dissemination of information. (b) National Digestive Diseases Data System and National Digestive Diseases Information Clearinghouse The Director of the Institute shall (1) establish the National Digestive Diseases Data System for the collection, storage, analysis, retrieval, and dissemination of data derived from patient populations with digestive diseases, including, where possible, data involving general populations for the purpose of detection of individuals with a risk of developing digestive diseases, and (2) establish the National Digestive Diseases Information Clearinghouse to facilitate and enhance knowledge and understanding of digestive diseases on the part of health professionals, patients, and the public through the effective dissemination of information. (c) National Kidney and Urologic Diseases Data System and National Kidney and Urologic Diseases Information Clearinghouse The Director of the Institute shall (1) establish the National Kidney and Urologic Diseases Data System for the collection, storage, analysis, retrieval, and dissemination of data derived from patient populations with kidney and urologic diseases, including, where possible, data involving general populations for the purpose of detection of individuals with a risk of developing kidney and urologic diseases, and (2) establish the National Kidney and Urologic Diseases Information Clearinghouse to facilitate and enhance knowledge and understanding of kidney and urologic diseases on the part of health professionals, patients, and the public through the effective dissemination of information.4 other bills also change this section · Follow it → Official text at uscode.house.gov ↗
-
§ 285c-2 Division Directors for Diabetes, Endocrinology, and Metabolic Diseases, Digestive Diseases and Nutrition, and Kidney, Urologic, and Hematologic Diseases; functions Amends
42 U.S.C. § 285c-2
The law today
(a) (1) In the Institute there shall be a Division Director for Diabetes, Endocrinology, and Metabolic Diseases, a Division Director for Digestive Diseases and Nutrition, and a Division Director for Kidney, Urologic, and Hematologic Diseases. Such Division Directors, under the supervision of the Director of the Institute, shall be responsible for— (A) developing a coordinated plan (including recommendations for expenditures) for each of the national research institutes within the National Institutes of Health with respect to research and training concerning diabetes, endocrine and metabolic diseases, digestive diseases and nutrition, and kidney, urologic, and hematologic diseases; (B) assessing the adequacy of management approaches for the activities within such institutes concerning such diseases and nutrition and developing improved approaches if needed; (C) monitoring and reviewing expenditures by such institutes concerning such diseases and nutrition; and (D) identifying research opportunities concerning such diseases and nutrition and recommending ways to utilize such opportunities. (2) The Director of the Institute shall transmit to the Director of NIH the plans, recommendations, and reviews of the Division Directors under subparagraphs (A) through (D) of paragraph (1) together with such comments and recommendations as the Director of the Institute determines appropriate. (b) The Director of the Institute, acting through the Division Director for Diabetes, Endocrinology, and Metabolic Diseases, the Division Director for Digestive Diseases and Nutrition, and the Division Director for Kidney, Urologic, and Hematologic Diseases, shall— (1) carry out programs of support for research and training (other than training for which Ruth L. Kirschstein National Research Service Awards may be made under section 288 of this title) in the diagnosis, prevention, and treatment of diabetes mellitus and endocrine and metabolic diseases, digestive diseases and nutritional disorders, and kidney, urologic, and hematologic diseases, including support for training in medical schools, graduate clinical training, graduate training in epidemiology, epidemiology studies, clinical trials, and interdisciplinary research programs; and (2) establish programs of evaluation, planning, and dissemination of knowledge related to such research and training.4 other bills also change this section · Follow it → Official text at uscode.house.gov ↗
-
§ 285c-3 Interagency coordinating committees Amends
42 U.S.C. § 285c-3 — at 285c-3(a)
The law today
(a) Establishment and purpose For the purpose of— (1) better coordination of the research activities of all the national research institutes relating to diabetes mellitus, digestive diseases, and kidney, urologic, and hematologic diseases; and (2) coordinating those aspects of all Federal health programs and activities relating to such diseases to assure the adequacy and technical soundness of such programs and activities and to provide for the full communication and exchange of information necessary to maintain adequate coordination of such programs and activities; the Secretary shall establish a Diabetes Mellitus Interagency Coordinating Committee, a Digestive Diseases Interagency Coordinating Committee, and a Kidney, Urologic, and Hematologic Diseases Coordinating Committee (hereafter in this section individually referred to as a “Committee”). (b) Membership; chairman; meetings Each Committee shall be composed of the Directors of each of the national research institutes and divisions involved in research with respect to the diseases for which the Committee is established, the Division Director of the Institute for the diseases for which the Committee is established, the Under Secretary for Health of the Department of Veterans Affairs, and the Assistant Secretary of Defense for Health Affairs (or the designees of such officers) and shall include representation from all other Federal departments and agencies whose programs involve health functions or responsibilities relevant to such diseases, as determined by the Secretary. Each Committee shall be chaired by the Director of NIH (or the designee of the Director). Each Committee shall meet at the call of the chairman, but not less often than four times a year.6 other bills also change this section · Follow it → Official text at uscode.house.gov ↗
-
§ 285c-4 Advisory boards Amends
42 U.S.C. § 285c-4
The law today
(a) Establishment The Secretary shall establish in the Institute the National Diabetes Advisory Board, the National Digestive Diseases Advisory Board, and the National Kidney and Urologic Diseases Advisory Board (hereafter in this section individually referred to as an “Advisory Board”). (b) Membership; ex officio members Each Advisory Board shall be composed of eighteen appointed members and nonvoting ex officio members as follows: (1) The Secretary shall appoint— (A) twelve members from individuals who are scientists, physicians, and other health professionals, who are not officers or employees of the United States, and who represent the specialties and disciplines relevant to the diseases with respect to which the Advisory Board is established; and (B) six members from the general public who are knowledgeable with respect to such diseases, including at least one member who is a person who has such a disease and one member who is a parent of a person who has such a disease. Of the appointed members at least five shall by virtue of training or experience be knowledgeable in the fields of health education, nursing, data systems, public information, and community program development. (2) (A) The following shall be ex officio members of each Advisory Board: (i) The Assistant Secretary for Health, the Director of NIH, the Director of the National Institute of Diabetes and Digestive and Kidney Diseases, the Director of the Centers for Disease Control and Prevention, the Under Secretary for Health of the Department of Veterans Affairs, the Assistant Secretary of Defense for Health Affairs, and the Division Director of the National Institute of Diabetes and Digestive and Kidney Diseases for the diseases for which the Board is established (or the designees of such officers). (ii) Such other officers and employees of the United States as the Secretary determines necessary for the Advisory Board to carry out its functions. (B) In the case of the National Diabetes Advisory Board, the following shall also be ex officio members: The Director of the National Heart, Lung, and Blood Institute, the Director of the National Eye Institute, the Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the Administrator of the Health Resources and Services Administration (or the designees of such officers). (c) Compensation Members of an Advisory Board who are officers or employees of the Federal Government shall serve as members of the Advisory Board without compensation in addition to that received in their regular public employment. Other members of the Board shall receive compensation at rates not to exceed the daily equivalent of the annual rate in effect for grade GS–18 of the General Schedule for each day (including traveltime) they are engaged in the performance of their duties as members of the Board. (d) Term of office; vacancy The term of office of an appointed member of an Advisory Board is four years, except that no term of office may extend beyond the expiration of the Advisory Board. Any member appointed to fill a vacancy for an unexpired term shall be appointed for the remainder of such term. A member may serve after the expiration of the member’s term until a successor has taken office. If a vacancy occurs in an Advisory Board, the Secretary shall make an appointment to fill the vacancy not later than 90 days from the date the vacancy occurred. (e) Chairman The members of each Advisory Board shall select a chairman from among the appointed members. (f) Executive director; professional and clerical staff; administrative support services and facilities The Secretary shall, after consultation with and consideration of the recommendations of an Advisory Board, provide the Advisory Board with an executive director and one other professional staff member. In addition, the Secretary shall, after consultation with and consideration of the recommendations of the Advisory Board, provide the Adv...4 other bills also change this section · Follow it → Official text at uscode.house.gov ↗
-
§ 285c-5 Research and training centers; development or expansion Amends
42 U.S.C. § 285c-5
The law today
(a) Diabetes mellitus and related endocrine and metabolic diseases (1) Consistent with applicable recommendations of the National Commission on Diabetes, the Director of the Institute shall provide for the development or substantial expansion of centers for research and training in diabetes mellitus and related endocrine and metabolic diseases. Each center developed or expanded under this subsection shall— (A) utilize the facilities of a single institution, or be formed from a consortium of cooperating institutions, meeting such research and training qualifications as may be prescribed by the Secretary; and (B) conduct— (i) research in the diagnosis and treatment of diabetes mellitus and related endocrine and metabolic diseases and the complications resulting from such diseases; (ii) training programs for physicians and allied health personnel in current methods of diagnosis and treatment of such diseases and complications, and in research in diabetes; and (iii) information programs for physicians and allied health personnel who provide primary care for patients with such diseases or complications. (2) A center may use funds provided under paragraph (1) to provide stipends for nurses and allied health professionals enrolled in research training programs described in paragraph (1)(B)(ii). (b) Digestive diseases and related functional, congenital, metabolic disorders, and normal development of digestive tract Consistent with applicable recommendations of the National Digestive Diseases Advisory Board, the Director shall provide for the development or substantial expansion of centers for research in digestive diseases and related functional, congenital, metabolic disorders, and normal development of the digestive tract. Each center developed or expanded under this subsection— (1) shall utilize the facilities of a single institution, or be formed from a consortium of cooperating institutions, meeting such research qualifications as may be prescribed by the Secretary; (2) shall develop and conduct basic and clinical research into the cause, diagnosis, early detection, prevention, control, and treatment of digestive diseases and nutritional disorders and related functional, congenital, or metabolic complications resulting from such diseases or disorders; (3) shall encourage research into and programs for— (A) providing information for patients with such diseases and the families of such patients, physicians and others who care for such patients, and the general public; (B) model programs for cost effective and preventive patient care; and (C) training physicians and scientists in research on such diseases, disorders, and complications; and (4) may perform research and participate in epidemiological studies and data collection relevant to digestive diseases and disorders and disseminate such research, studies, and data to the health care profession and to the public. (c) Kidney and urologic diseases The Director shall provide for the development or substantial expansion of centers for research in kidney and urologic diseases. Each center developed or expanded under this subsection— (1) shall utilize the facilities of a single institution, or be formed from a consortium of cooperating institutions, meeting such research qualifications as may be prescribed by the Secretary; (2) shall develop and conduct basic and clinical research into the cause, diagnosis, early detection, prevention, control, and treatment of kidney and urologic diseases; (3) shall encourage research into and programs for— (A) providing information for patients with such diseases, disorders, and complications and the families of such patients, physicians and others who care for such patients, and the general public; (B) model programs for cost effective and preventive patient care; and (C) training physicians and scientists in research on such diseases; and (4) may perform research and participate in epidemiological studies and data collection relevant to kidney a...6 other bills also change this section · Follow it → Official text at uscode.house.gov ↗
-
§ 285c-6 Advisory council subcommittees Amends
42 U.S.C. § 285c-6
The law today
There are established within the advisory council for the Institute appointed under section 284a of this title a subcommittee on diabetes and endocrine and metabolic diseases, a subcommittee on digestive diseases and nutrition, and a subcommittee on kidney, urologic, and hematologic diseases. The subcommittees shall be composed of members of the advisory council who are outstanding in the diagnosis, prevention, and treatment of the diseases for which the subcommittees are established and members of the advisory council who are leaders in the fields of education and public affairs. The subcommittees are authorized to review applications made to the Director of the Institute for grants for research and training projects relating to the diagnosis, prevention, and treatment of the diseases for which the subcommittees are established and shall recommend to the advisory council those applications and contracts that the subcommittees determine will best carry out the purposes of the Institute. The subcommittees shall also review and evaluate the diabetes and endocrine and metabolic diseases, digestive diseases and nutrition, and kidney, urologic, and hematologic diseases programs of the Institute and recommend to the advisory council such changes in the administration of such programs as the subcommittees determine are necessary.4 other bills also change this section · Follow it → Official text at uscode.house.gov ↗
Action History
-
Introduced in Senate
-
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsors
- Tammy Duckworth · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 546 not signed on
Sponsors (1)
- Duckworth, Tammy Democratic
Co-sponsors (0)
None.
Not signed on (546)
546 members have not signed on to this bill.
Show all 546 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- Who sponsors S 3074?
- S 3074 is sponsored by Duckworth, Tammy (Democratic).
- What is the current status of S 3074?
- This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track S 3074?
- Track S 3074 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on S 3074
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of S 3074
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →